Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Extended validation of the RR6 prognostic model at 6 and 12 months in primary and secondary myelofibrosis patients treated with ruxolitinib

Erika Morsia, Dorela Lame, Michelangelo Pianelli, Giorgio Gramazio, Sonia More', Shahram Kordasti, Serena Rupoli, Antonella Poloni

Blood (2025) 146 (Supplement 1): 7350.

https://doi.org/10.1182/blood-2025-7350

Published: 2025

Journal Articles

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Uwe Platzbecker, Elena Crisa, Sophie Salazar, Thomas Cluzeau, Antonella Poloni, Raquel De Paz Arias, Thibault Comont, Sebastian Grosicki, Aristoteles Giagounidis, Matteo Della Porta, Pellegrino Musto, Mar Tormo, Dominic Brauer, Ana Alfonso-Pierola, Stefania Paolini, Sophie Park, Annelies Weyn, Lionel Ades, Valeria Santini

Blood (2025) 146 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2025-5649

Published: 2025

Journal Articles

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Luca Lanino, Matteo Zampini, Ivan Civettini, Daniele Ramazzotti, Alessia Campagna, Elena Riva, Denise Ventura, Nicole Pinocchio, Pasquale Niscola, Marco Gabriele Raddi, Angela Consagra, Federica Pilo, Antonella Poloni, Mariarita Sciumè, Andrea Patriarca, Stefania Paolini, Carlo Finelli, Andrea Castelli, Pellegrino Musto, Anna Calvisi, Grazia Sanpaolo, Monia Marchetti, Elisa Diral, Germana Beltrami, Carmen Fava, Claudio Fozza, Chiara Frairia, Carmine Selleri, Daniela Barraco, Domenico Pastore, Rosanna Ciancia, Elena Crisa, Enrico Balleari, Susanna Gallo, Vincenzo Pavone, Esther Natalie Oliva, Giulia Maggioni, Ferdinando Frigeri, Gabriele Todisco, Antonio Russo, Alessandro Buizza, Ivan Ferrari, Giulia Figini, Alessandra Crespi, Elisa Calvetti, Chiara Milanesi, Nicla Manes, Francesco Pesce, Saverio D'Amico, Gianluca Asti, Elisabetta Sauta, Guido Sanguinetti, Gastone Castellani, Marilena Bicchieri, Ilaria Naldi, Francesca Ficara, Valeria Santini, Marta Ubezio, Matteo Della Porta

Blood (2025) 146 (Supplement 1): 3842.

https://doi.org/10.1182/blood-2025-3842

Published: 2025

Journal Articles

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Anna Calvisi, Rosangela Filiberti, Daniela Barraco, Massimo Bernardi, Isabella Capodanno, Andrea Castelli, Rosanna Ciancia, Carmen Fava, Carla Fili, Chiara Frairia, Francesco Frattini, Piero Galieni, Pasquale Niscola, Stefania Paolini, Andrea Patriarca, Anna Maria Pelizzari, Grazia Sanpaolo, Carmine Selleri, Francesco Alesiani, Gianni Binotto, Costanza Bosi, Catello Califano, Barbara Castagnari, Elena Crisa, Monica Crugnola, Marco De Gobbi, Matteo Della Porta, Nicola Di Renzo, Dario Ferrero, Carlo Finelli, Carla Foli, Claudio Fozza, Maurizio Frezzato, Ferdinando Frigeri, Gianluca Guaragna, Monia Marchetti, Daniele G. Mattei, Mara Memoli, Paola Minetto, Alfredo Molteni, Pellegrino Musto, Esther Natalie Oliva, Giuseppe Alberto Palumbo, Fabrizio Pane, Giuseppe Pietrantuono, Federica Pilo, Antonella Poloni, Giulia Rivoli, Mariarita Sciumè, Rodolfo Tassara, Mauro Turrini, Letizia Zannoni, Ilaria Naldi, Enrico Balleari, Valeria Santini, Francesco Onida

Blood (2025) 146 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2025-2080

Published: 2025

Journal Articles

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Blood (2025) 146 (Supplement 1): 4002.

https://doi.org/10.1182/blood-2025-4002

Published: 2025

Journal Articles

Cytokine signatures predict response, progression, and immune-related toxicity in Sézary syndrome patients treated with mogamulizumab

Erika Morsia, Laura Gurguglione, Riccardo Ceccarelli, Sonia More', Shahram Kordasti, Antonella Poloni, Serena Rupoli

Blood (2025) 146 (Supplement 1): 5430.

https://doi.org/10.1182/blood-2025-5430

Published: 2025

Journal Articles

Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix)

Blood (2025) 146 (Supplement 1): 5631.

https://doi.org/10.1182/blood-2025-5631

Published: 2025

Journal Articles

Association of Hypometilating Agents + Venetoclax in the Treatment of Secondary Acute Myeloid Leukemias Evolved from Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 6711.

https://doi.org/10.1182/blood-2024-207060

Published: 2024

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis

Sonia More', Valentina Maria Manieri, Laura Corvatta, Erika Morsia, Shahram Kordasti, Attilio Olivieri, Antonella Poloni, Massimo Offidani

Blood (2024) 144 (Supplement 1): 3323.

https://doi.org/10.1182/blood-2024-205518

Published: 2024

Journal Articles

Luspatercept for the Treatment of Transfusion-Dependent Anemia in Patients with Myelodysplastic Neoplasms with del5q, Refractory/Resistant/Intolerant to Prior Treatments (QOL-ONE Phoenix)

Esther Natalie Oliva, Antonella Poloni, Chiara Frairia, Marta Riva, Isabella Capodanno, Ilaria Maria Delfino, Maria Grazia D'Errigo, Corrado Mammì, Giuseppe Ianni', Gina Zini, Davide Griguolo, Monia Marchetti, Carmelo Gurnari, Maria Teresa Voso, Bruno Fattizzo

Blood (2024) 144 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2024-205325

Published: 2024

Journal Articles

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

Erika Morsia, Paola Ranalli, Stefano Baldoni, Dorela Lame, Sonia More', Gaetano La Barba, Fabiola Saladino, Antonella Poloni, Attilio Olivieri, Serena Rupoli, Mauro Di Ianni, Shahram Kordasti

Blood (2024) 144 (Supplement 1): 6645.

https://doi.org/10.1182/blood-2024-207881

Published: 2024

Journal Articles

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Blood (2024) 144 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2024-194413

Published: 2024

Journal Articles

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Blood (2023) 142 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2023-190091

Published: 2023

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience

Dorela Lame, Marianeve Caprino, Elena Marinelli Busilacchi, Nadia Viola, Erika Morsia, Michelangelo Pianelli, Shahram Kordasti, Attilio Olivieri, Antonella Poloni

Blood (2022) 140 (Supplement 1): 6923–6924.

https://doi.org/10.1182/blood-2022-169820

Published: 2022

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

Epidemiology and Risk Factors for Infections in Myelodysplastic Syndromes

Antonella Poloni, Alberto Carturan, Michelangelo Pianelli, Erika Morsia, Dorela Lame, Attilio Olivieri

Blood (2021) 138 (Supplement 1): 4667.

https://doi.org/10.1182/blood-2021-150303

Published: 2021

Journal Articles

Breakthroughs in Preclinical Development of Ataluren (PTC124) As Therapeutic Option for Patients Affected By Shwachman-Diamond Syndrome: Towards the First Clinical Trial

Valentino Bezzerri, PhD, Antonio Vella, PhD, Elisabetta D'Aversa, PhD, Martina Api, PhD, Marisole Allegri, MSc, Elena Marinelli Busilacchi, PhD, Giovanna D'Amico, BSc, PhD MSc, Roberto Gambari, PhD, Claudio Sorio, MD PhD, Benedetta Fabrizzi, MD, Vincenzo Bronte, MD, Antonella Poloni, PhD MD, Monica Borgatti, PhD, Marco Cipolli, MD

Blood (2019) 134 (Supplement_1): 451.

https://doi.org/10.1182/blood-2019-127866

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Extended validation of the RR6 prognostic model at 6 and 12 months in primary and secondary myelofibrosis patients treated with ruxolitinib

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Cytokine signatures predict response, progression, and immune-related toxicity in Sézary syndrome patients treated with mogamulizumab

Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix)

Association of Hypometilating Agents + Venetoclax in the Treatment of Secondary Acute Myeloid Leukemias Evolved from Chronic Myelomonocytic Leukemia

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis

Luspatercept for the Treatment of Transfusion-Dependent Anemia in Patients with Myelodysplastic Neoplasms with del5q, Refractory/Resistant/Intolerant to Prior Treatments (QOL-ONE Phoenix)

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Epidemiology and Risk Factors for Infections in Myelodysplastic Syndromes

Breakthroughs in Preclinical Development of Ataluren (PTC124) As Therapeutic Option for Patients Affected By Shwachman-Diamond Syndrome: Towards the First Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only